Simultaneous blockade of adenosine A2A and metabotropic glutamate mGlu5 receptors increase their efficacy in reversing Parkinsonian deficits in rats
Identifieur interne : 003411 ( Main/Merge ); précédent : 003410; suivant : 003412Simultaneous blockade of adenosine A2A and metabotropic glutamate mGlu5 receptors increase their efficacy in reversing Parkinsonian deficits in rats
Auteurs : Roberto Coccurello [France] ; Nathalie Breysse [France] ; Marianne Amalric [France]Source :
- Neuropsychopharmacology : (New York, NY) [ 0893-133X ] ; 2004.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
Abstract
Recent evidence suggest that antagonism of adenosine A2A receptors represent an alternative therapeutic approach to Parkinson's disease (PD). Coactivation of A2A and the glutamate subtype 5 metabotropic receptors (mGlu5) synergistically stimulates DARPP-32 phosphorylation and c-fos expression in the striatum. This study therefore tested the effects of a joint blockade of these receptors to alleviate the motor dysfunction in a rat model of PD. 6-Hydroxydopamine infusions in the striatum produced akinetic deficits in rats trained to release a lever after a stimulus in a reaction time (RT) task. At 2 weeks after the lesion, A2A and mGlus receptors selective antagonists 8-(3-chlorostyryl)caffeine (CSC) and 2-methyl-6-(phenylethynyl)-pyridine (MPEP) were administered daily for 3 weeks either as a single or joint treatment. Injections of CSC (1.25 mg/kg) and MPEP (1.5 mg/kg) separately or in combination reduced the increase of delayed responses and RTs induced by 6-OHDA lesions, while the same treatment had no effect in controls. Furthermore, coadministration of lower doses of 0.625 mg/kg CSC and 0.375 mg/kg MPEP noneffective as a single treatment promoted a full and immediate recovery of akinesia, which was found to be more efficient than the separate blockade of these receptors. These results demonstrate that the combined inactivation of A2A and mGlu5 receptor potentiate their beneficial effects supporting this pharmacological strategy as a promising anti-Parkinsonian therapy.
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 000D79
- to stream PascalFrancis, to step Curation: 000655
- to stream PascalFrancis, to step Checkpoint: 000C11
Links to Exploration step
Pascal:04-0439077Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Simultaneous blockade of adenosine A<sub>2A</sub> and metabotropic glutamate mGlu<sub>5</sub> receptors increase their efficacy in reversing Parkinsonian deficits in rats</title><author><name sortKey="Coccurello, Roberto" sort="Coccurello, Roberto" uniqKey="Coccurello R" first="Roberto" last="Coccurello">Roberto Coccurello</name><affiliation wicri:level="4"><inist:fA14 i1="01"><s1>Laboratoire de Neurobiologie de la Cognition, CNRS and Université de Provence</s1><s2>Marseille</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Provence-Alpes-Côte d'Azur</region><region type="old region">Provence-Alpes-Côte d'Azur</region><settlement type="city">Marseille</settlement></placeName><orgName type="university">Université de Provence</orgName></affiliation></author><author><name sortKey="Breysse, Nathalie" sort="Breysse, Nathalie" uniqKey="Breysse N" first="Nathalie" last="Breysse">Nathalie Breysse</name><affiliation wicri:level="4"><inist:fA14 i1="01"><s1>Laboratoire de Neurobiologie de la Cognition, CNRS and Université de Provence</s1><s2>Marseille</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Provence-Alpes-Côte d'Azur</region><region type="old region">Provence-Alpes-Côte d'Azur</region><settlement type="city">Marseille</settlement></placeName><orgName type="university">Université de Provence</orgName></affiliation></author><author><name sortKey="Amalric, Marianne" sort="Amalric, Marianne" uniqKey="Amalric M" first="Marianne" last="Amalric">Marianne Amalric</name><affiliation wicri:level="4"><inist:fA14 i1="01"><s1>Laboratoire de Neurobiologie de la Cognition, CNRS and Université de Provence</s1><s2>Marseille</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Provence-Alpes-Côte d'Azur</region><region type="old region">Provence-Alpes-Côte d'Azur</region><settlement type="city">Marseille</settlement></placeName><orgName type="university">Université de Provence</orgName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">04-0439077</idno><date when="2004">2004</date><idno type="stanalyst">PASCAL 04-0439077 INIST</idno><idno type="RBID">Pascal:04-0439077</idno><idno type="wicri:Area/PascalFrancis/Corpus">000D79</idno><idno type="wicri:Area/PascalFrancis/Curation">000655</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000C11</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000C11</idno><idno type="wicri:doubleKey">0893-133X:2004:Coccurello R:simultaneous:blockade:of</idno><idno type="wicri:Area/Main/Merge">003411</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Simultaneous blockade of adenosine A<sub>2A</sub> and metabotropic glutamate mGlu<sub>5</sub> receptors increase their efficacy in reversing Parkinsonian deficits in rats</title><author><name sortKey="Coccurello, Roberto" sort="Coccurello, Roberto" uniqKey="Coccurello R" first="Roberto" last="Coccurello">Roberto Coccurello</name><affiliation wicri:level="4"><inist:fA14 i1="01"><s1>Laboratoire de Neurobiologie de la Cognition, CNRS and Université de Provence</s1><s2>Marseille</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Provence-Alpes-Côte d'Azur</region><region type="old region">Provence-Alpes-Côte d'Azur</region><settlement type="city">Marseille</settlement></placeName><orgName type="university">Université de Provence</orgName></affiliation></author><author><name sortKey="Breysse, Nathalie" sort="Breysse, Nathalie" uniqKey="Breysse N" first="Nathalie" last="Breysse">Nathalie Breysse</name><affiliation wicri:level="4"><inist:fA14 i1="01"><s1>Laboratoire de Neurobiologie de la Cognition, CNRS and Université de Provence</s1><s2>Marseille</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Provence-Alpes-Côte d'Azur</region><region type="old region">Provence-Alpes-Côte d'Azur</region><settlement type="city">Marseille</settlement></placeName><orgName type="university">Université de Provence</orgName></affiliation></author><author><name sortKey="Amalric, Marianne" sort="Amalric, Marianne" uniqKey="Amalric M" first="Marianne" last="Amalric">Marianne Amalric</name><affiliation wicri:level="4"><inist:fA14 i1="01"><s1>Laboratoire de Neurobiologie de la Cognition, CNRS and Université de Provence</s1><s2>Marseille</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Provence-Alpes-Côte d'Azur</region><region type="old region">Provence-Alpes-Côte d'Azur</region><settlement type="city">Marseille</settlement></placeName><orgName type="university">Université de Provence</orgName></affiliation></author></analytic><series><title level="j" type="main">Neuropsychopharmacology : (New York, NY)</title><title level="j" type="abbreviated">Neuropsychopharmacology : (NY NY)</title><idno type="ISSN">0893-133X</idno><imprint><date when="2004">2004</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Neuropsychopharmacology : (New York, NY)</title><title level="j" type="abbreviated">Neuropsychopharmacology : (NY NY)</title><idno type="ISSN">0893-133X</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>A2A adenosine receptor</term><term>Animal</term><term>Antagonist</term><term>Antiparkinson agent</term><term>Glutamate receptor</term><term>Mechanism of action</term><term>Metabotropic receptor</term><term>Parkinson disease</term><term>Rat</term><term>Reaction time</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Parkinson maladie</term><term>Récepteur métabotropique</term><term>Récepteur glutamate</term><term>Animal</term><term>Rat</term><term>Temps réaction</term><term>Antagoniste</term><term>Récepteur adénosinique A2A</term><term>Antiparkinsonien</term><term>Mécanisme action</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Recent evidence suggest that antagonism of adenosine A<sub>2A</sub> receptors represent an alternative therapeutic approach to Parkinson's disease (PD). Coactivation of A<sub>2A</sub> and the glutamate subtype 5 metabotropic receptors (mGlu<sub>5</sub>) synergistically stimulates DARPP-32 phosphorylation and c-fos expression in the striatum. This study therefore tested the effects of a joint blockade of these receptors to alleviate the motor dysfunction in a rat model of PD. 6-Hydroxydopamine infusions in the striatum produced akinetic deficits in rats trained to release a lever after a stimulus in a reaction time (RT) task. At 2 weeks after the lesion, A<sub>2A</sub> and mGlus receptors selective antagonists 8-(3-chlorostyryl)caffeine (CSC) and 2-methyl-6-(phenylethynyl)-pyridine (MPEP) were administered daily for 3 weeks either as a single or joint treatment. Injections of CSC (1.25 mg/kg) and MPEP (1.5 mg/kg) separately or in combination reduced the increase of delayed responses and RTs induced by 6-OHDA lesions, while the same treatment had no effect in controls. Furthermore, coadministration of lower doses of 0.625 mg/kg CSC and 0.375 mg/kg MPEP noneffective as a single treatment promoted a full and immediate recovery of akinesia, which was found to be more efficient than the separate blockade of these receptors. These results demonstrate that the combined inactivation of A<sub>2A</sub> and mGlu<sub>5</sub> receptor potentiate their beneficial effects supporting this pharmacological strategy as a promising anti-Parkinsonian therapy.</div></front></TEI><affiliations><list><country><li>France</li></country><region><li>Provence-Alpes-Côte d'Azur</li></region><settlement><li>Marseille</li></settlement><orgName><li>Université de Provence</li></orgName></list><tree><country name="France"><region name="Provence-Alpes-Côte d'Azur"><name sortKey="Coccurello, Roberto" sort="Coccurello, Roberto" uniqKey="Coccurello R" first="Roberto" last="Coccurello">Roberto Coccurello</name></region><name sortKey="Amalric, Marianne" sort="Amalric, Marianne" uniqKey="Amalric M" first="Marianne" last="Amalric">Marianne Amalric</name><name sortKey="Breysse, Nathalie" sort="Breysse, Nathalie" uniqKey="Breysse N" first="Nathalie" last="Breysse">Nathalie Breysse</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003411 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 003411 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= Main
|étape= Merge
|type= RBID
|clé= Pascal:04-0439077
|texte= Simultaneous blockade of adenosine A2A and metabotropic glutamate mGlu5 receptors increase their efficacy in reversing Parkinsonian deficits in rats
}}
| This area was generated with Dilib version V0.6.29. |  |